Evolv Technologies Holdings, Inc. (EVLV) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.01 per share a year ago.
Evolv Technologies operates a hardware-enabled subscription model with a proprietary data moat, screening over 4 million people daily across 8,000 systems. EVLV achieved 40% revenue growth in 2025 and raised 2026 guidance, now targeting $172–$178 million in revenue and 20–25% ARR growth. Direct fulfillment of hardware is creating near-term gross margin headwinds but increases total gross profit and revenue over contract life.
The mean of analysts' price targets for Evolv Technologies (EVLV) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 81.8% in Evolv Technologies (EVLV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Weave Communications is bringing AI receptionists to healthcare offices, automating scheduling, calls, and patient communication. Evolv Technologies and Pagaya Technologies use AI-driven data to improve security screening and expand access to credit.
Evolv Technologies Inc. NASDAQ: EVLV is a leader in AI weapons/gun/concealed weapon detection. The company delivered its fourth-quarter earnings report after the market closed on March 10.
Evolv Technologies Holdings, Inc. (EVLV) Q4 2025 Earnings Call Transcript
Evolv Technologies Holdings, Inc. (EVLV) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.1 per share a year ago.
Small-cap stocks have quietly been building a case that the broader market is finally paying attention to.
Over the past month here at the Sunday Digest, I've been lining up my top bets for 2026: Rocket Cos. Inc. ( RKT ) Crispr Therapeutics AG ( CRSP ) Evolv Technologies Holdings Inc. ( EVLV ) Celanese Corp. ( CE ) Akamai Technologies Inc. ( AKAM ) PayPal Holdings Inc. ( PYPL ) FactSet Research Systems Inc. ( FDS ) Tronox Holdings PLC ( TROX ) This list spans from the ultraconservative FactSet to the high-growth startup Evolv, and features virtually everything in between.
As 2026 unfolds with mega-cap stocks still dominating, there are several smaller companies capable of turning modest investments into multi-million-dollar returns over the coming years.
The Russell 2000 is ending the year on a strong note. As of Dec. 18, the small cap index is up about 11% for the year.